<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03790891</url>
  </required_header>
  <id_info>
    <org_study_id>2018-127</org_study_id>
    <nct_id>NCT03790891</nct_id>
  </id_info>
  <brief_title>Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy</brief_title>
  <official_title>Adoptive Immunotherapy for Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timmune Biotech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Timmune Biotech Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, early phase Ⅰ study, to determine the safety and efficacy
      of CD19-TriCAR-T and CD19-TriCAR-SILK cell therapy in Non-Hodgkin lymphoma treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD19-TriCAR contains an anti-CD19 scFv, a PD-L1 blocker, and a cytokine complex, enabling the
      CD19-TriCAR-T/SILK to simultaneously targeting the CD19 positive Non-Hodgkin
      lymphoma，blocking the inhibitory PD-L1 signal and stimulating innate T/NK cell activation and
      expansion, thus make it a tri-functional CAR (Tri-CAR). CD19-TriCAR-T is an autologous
      tri-functional CAR-T cell therapy, CD19-TriCAR-SILK is an Allogeneic tri-functional CAR-NK
      cell therapy, patients ineligible for leukapheresis or CAR-T therapy will be recommended for
      CD19-TriCAR-SILK therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety （Incidence of treatment-related adverse events as assessed by CTCAE v4.03）</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of treatment-related adverse events as assessed by CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate[CR] (Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma)</measure>
    <time_frame>24 months</time_frame>
    <description>Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response rate [PR] （Partial response rate per the revised International Working Group (IWG) Response Criteria）</measure>
    <time_frame>24 months</time_frame>
    <description>Partial response rate per the revised International Working Group (IWG) Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response （The time from response to relapse or progression）</measure>
    <time_frame>24 months</time_frame>
    <description>The time from response to relapse or progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival （The time from the first day of treatment to the date on which disease progresses）</measure>
    <time_frame>24 months</time_frame>
    <description>The time from the first day of treatment to the date on which disease progresses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival （The number of patient alive, with or without signs of cancer）</measure>
    <time_frame>24 months</time_frame>
    <description>The number of patient alive, with or without signs of cancer</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>CD19-TriCAR-T/SILK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD19-TriCAR-T/SILK cells will be administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19-TriCAR-T/SILK</intervention_name>
    <description>A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.</description>
    <arm_group_label>CD19-TriCAR-T/SILK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All subjects must personally sign and date the consent form before initiating any
             study specific procedures or activities;

          2. All subjects must be able to comply with all the scheduled procedures in the study;

          3. Refractory or relapsed malignant Non-Hodgkin lymphoma, defined as one or more of the
             following: Relapsed in 6 months after most recent therapy; Progressive disease in
             standard chemotherapy; Disease progression or relapsed in ≤12 months of ASCT;

          4. At least one measurable lesion per revised IWG Response Criteria;

          5. Aged ＜70 years;

          6. Expected survival ≥12 weeks; Eastern cooperative oncology group (ECOG) performance
             status of≤2;

          7. Systematic usage of immunosuppressive drug or corticosteroid must have been stopped
             for more than 4 weeks;

          8. All other treatment induced adverse events must have been resolved to ≤grade 1;

          9. Laboratory tests must fulfill the following criteria: ANC ≥ 1000/uL, HGB&gt;70g/L,
             Platelet count ≥ 50,000/uL, Creatinine clearance ≤1.5 ULN, Serum ALT/AST ≤2.5 ULN,
             Total bilirubin ≤1.5 ULN (except in subjects with Gilbert's syndrome);

        Exclusion Criteria:

          1. Presence of fungal, bacterial, viral, or other infection that is hardly to
             control（defined by investigator）;

          2. Patients with symptomatic central nervous system metastasis, intracranial metastasis,
             and cancer cells found in cerebrospinal fluid are not recommended to participate in
             this study. Symptom free or post-treatment stable disease or disappearance of lesions
             should not be excluded. The specific selection is ultimately determined by the
             investigator;

          3. Lactating women or women of childbearing age who plan to conceive during the time
             period;

          4. Active infection with hepatitis B (HBsAG positive) or hepatitis C virus (anti-HCV
             positive);

          5. Known history of infection with HIV;

          6. Subjects need systematic usage of corticosteroid;

          7. Subjects need systematic usage of immunosuppressive drug;

          8. Planed operation, history of other related disease, or any other related laboratory
             tests restrict patients for the study;

          9. Other reasons the investigator consider the patient may not be suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yao Hongxia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hainan General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yao Hongxia</last_name>
    <phone>+86 13876081106</phone>
    <email>yaohongxia768@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gao Bin</last_name>
    <phone>+86 13910899150</phone>
    <email>bin.gaoa@timmune.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hainan Cancer Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuyang Tian</last_name>
      <phone>+86 18686853849</phone>
      <email>tianyuyang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yao Hongxia</last_name>
      <phone>+86 13876081106</phone>
      <email>yaohongxia768@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wu Yasong</last_name>
      <phone>+86 18020091931</phone>
      <email>yasong.wu@timmune.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Hainan Medical University</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haifeng Lin</last_name>
      <phone>+86 13322060949</phone>
      <email>13322060949@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017 Jan 4;25(1):285-295. doi: 10.1016/j.ymthe.2016.10.020. Epub 2017 Jan 4.</citation>
    <PMID>28129122</PMID>
  </reference>
  <reference>
    <citation>Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19. Review.</citation>
    <PMID>28925994</PMID>
  </reference>
  <reference>
    <citation>Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018 Mar 2;11(1):35. doi: 10.1186/s13045-018-0571-y. Review. Erratum in: J Hematol Oncol. 2018 Jun 13;11(1):81.</citation>
    <PMID>29499750</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 28, 2018</study_first_submitted>
  <study_first_submitted_qc>December 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2019</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR-T</keyword>
  <keyword>TriCAR-T</keyword>
  <keyword>CD19-TriCAR-T</keyword>
  <keyword>CD19-TriCAR-SILK</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

